Drug Type Antibody |
Synonyms |
Target |
Mechanism CD43 inhibitors(JL1 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Kling Biotherapeutics BVStartup |
Active Organization Kling Biotherapeutics BVStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | NL | Kling Biotherapeutics BVStartup | 03 Jun 2024 |